Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907046 · ClinicalTrials.gov registry record · Phase 3
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
A Phase 3 study of Atrial Fibrillation and Intracerebral Hemorrhage, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT03907046 is a Phase 3 study of Atrial Fibrillation and Intracerebral Hemorrhage that is actively recruiting participants, run by Yale University. The registered enrollment target is 700 participants, below the 2,993-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT03907046, a Phase 3 study of Atrial Fibrillation and Intracerebral Hemorrhage, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Conditions Studied
Interventions
- DRUG Aspirin
- DRUG Apixaban
Study Locations (20)
California
- Mercy San Juan Medical Center - Carmichael
- Eden Medical Center, Castro Valley - Castro Valley
- Arrowhead Regional Medical Center - Colton
- Rancho Los Amigos National Rehabilitation Center - Downey
- Kaiser Permanente Fontana Medical Center - Fontana
- Community Regional Medical Center of Fresno - Fresno
- St. Jude Medical Center - Fullerton
- Long Beach Memorial Medical Center - Long Beach
- Los Alamitos Medical Center - Los Alamitos
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- Doctors Medical Center Modesto, Modesto, CA - Modesto
- Hoag Hospital Newport Beach - Newport Beach
Arizona
- Chandler Regional Medical Center - Chandler
- St. Joseph's Hospital and Medical Center - Phoenix
- Banner University Medical Center - Tucson
Alabama
- University of Alabama Hospital - Birmingham
- University of South Alabama University Hospital - Mobile
Arkansas
- UAMS Medical Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2027-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03907046
The ClinicalTrials.gov registry entry for NCT03907046 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,993-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (77% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.
NCT03907046 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT03907046 about?
NCT03907046 is a clinical study titled "Anticoagulation in ICH Survivors for Stroke Prevention and Recovery". Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in b...
What is the current status of trial NCT03907046?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2020-01-28. Estimated completion is 2027-04.
What conditions does trial NCT03907046 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Intracerebral Hemorrhage.
What interventions are being tested in trial NCT03907046?
The interventions under investigation include: Aspirin (DRUG), Apixaban (DRUG).
Who is sponsoring clinical trial NCT03907046?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03907046 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.